Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
27 Apr 2020
Long-term use of brivaracetam as an adjunctive treatment is well tolerated and effective in patients with focal seizures or primary generalized seizures, as shown in a study.
01 Apr 2019
Perampanel is safe and effective for treating refractory focal seizures in both Asian and non‐Asian populations, a study has found.
Rachel Soon, 24 Apr 2018

MIMS Pharmacist presents an overview of CoQ10's physiological role, as well as contemporary research on its pharmacology and effects.

Carvedilol plus ivabradine improves LVDD, survival in cirrhosis

23 Jun 2020

The combination of ivabradine and carvedilol improves left ventricular diastolic dysfunction (LVDD), achieves targeted heart rate reduction (THR) more often, and reduces the risk of encephalopathy, leading to improved survival in patients with cirrhosis, reveals a study.

The investigators randomized 189 cirrhotic patients with LVDD to THR (group A: n=94; carvedilol±ivabradine) or standard care (group B: n=95; no β-blockers) and followed them for 12 months. THR was defined as heart rate reduction to 55–65 beats per minute.

Eighty-eight patients (93 percent; responders) in group A achieved THR at 4 weeks: 48 (61.5 percent) with carvedilol alone and 40 (86.9 percent) of 46 patients with additional ivabradine. LVDD reversed in 16 (20.5 percent) and improved from grade 2 to 1 in 34 patients (35.4 percent) in group A. On the other hand, LVDD progressed from grade 1 to 2 in 10 patients (10.5 percent) in group B.

Twenty-one patients (11.1 percent) died at 12 months, six (14 percent) in group A and 15 (18 percent) in group B (p=0.240). However, there was no mortality seen in those who had persistent THR at 1 year (n=78; p=0.000).

Multivariate analysis revealed that model for end-stage liver disease (hazard ratio [HR], 1.52, 95 percent confidence interval [CI], 1.22–2.75; p=0.034] and E-wave transmitral/early diastolic mitral annular velocity (HR, 1.28, 95 percent CI, 1.23–2.42; p=0.048) were associated with 1-year mortality.

Mortality risk was higher among nonresponders (HR, 1.3, 95 percent CI, 1.2–1.8; p=0.046), independent of age, gender, and baseline model for end-stage liver disease. Responders, on the other hand, had reduced levels of norepinephrine, N terminal brain natriuretic peptide, plasma renin activity, and aldosterone (p<0.01).

More patients in group B developed acute kidney injury (odds ratio [OR], 4.2, 95 percent CI, 2.8–10.5; p=0.027) and encephalopathy (OR, 6.6, 95 percent CI, 1.9–9.7; p=0.040).

“LVDD refers to impaired cardiac diastolic relaxation and may be improved by THR,” the investigators noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
27 Apr 2020
Long-term use of brivaracetam as an adjunctive treatment is well tolerated and effective in patients with focal seizures or primary generalized seizures, as shown in a study.
01 Apr 2019
Perampanel is safe and effective for treating refractory focal seizures in both Asian and non‐Asian populations, a study has found.
Rachel Soon, 24 Apr 2018

MIMS Pharmacist presents an overview of CoQ10's physiological role, as well as contemporary research on its pharmacology and effects.